CERO_OUT_1 [2025-04-24 15:45:00 -0400] 6449 Bytes | 1712 tokens | Cum: 1712 tkns (21.40% of 8k)
==========================================================================

We need a winner today and it's already 3:44 PM on Thu Apr 24, 2025 ... So let's find out if CERo Therapeutics (CERO) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at $1.15 up from $0.7994. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: CERo Therapeutics (CERO)
IPO: 2024-02-15 (1 Year Ago)
Market Cap: $2,333,048
Shares Outstanding: 3,030,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

Here’s a list of headlines for CERo Therapeutics:

Today 08:15AM - CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
Apr-22-25 08:15AM - CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
Apr-10-25 08:15AM - CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236
Apr-09-25 08:15AM - CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
Mar-31-25 08:15AM - CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
Mar-27-25 08:15AM - CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
Mar-19-25 08:15AM - CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services
Mar-13-25 08:15AM - CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
Mar-06-25 08:15AM - CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays
Mar-05-25 08:15AM - CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14
Feb-06-25 08:15AM - CERo Therapeutics Holdings, Inc. Highlights Progress
Feb-05-25 08:00PM - CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Jan-07-25 08:13AM - Cero Therapeutics to effect 1-for-100 reverse stock split
Jan-06-25 08:00AM - CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
Dec-06-24 09:00AM - CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
Nov-15-24 08:45AM - CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
Nov-11-24 08:15AM - CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
Oct-21-24 09:00AM - CERo Therapeutics, Inc. Provides Corporate Update
Oct-02-24 09:15AM - CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
Sep-25-24 09:17AM - CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
Jul-08-24 08:00AM - CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024
Jun-13-24 08:15AM - CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-12-06T14:00:00Z - CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
B2 - 2024-06-13T12:15:00Z - CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
B3 - 2024-05-15T12:00:00Z - CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
B4 - 2024-03-28T18:08:52Z - Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B5 - 2024-03-20T12:20:39Z - Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
B6 - 2024-03-11T17:41:28Z - Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for CERo Therapeutics (CERO).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

CERO_OUT_3 [2025-04-24 15:45:00 -0400] 829 Bytes | 228 tokens | Cum: 1942 tkns (24.27% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/06/2993070/0/en/CERo-Therapeutics-Inc-Appoints-Chris-Ehrlich-CEO.htmlCERo Therapeutics Holdings, Inc. (CERO) has appointed Chris Ehrlich as its new CEO. The company is advancing the development of next-generation engineered T cell therapeutics for cancer treatment, with plans to initiate clinical trials for its lead product candidate CER-1236 in early 2025 for acute myeloid leukemia (AML).

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CERO_OUT_5 [2025-04-24 15:45:01 -0400] 879 Bytes | 277 tokens | Cum: 2221 tkns (27.76% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-24T18:43:12Z - Wall Street-Heavily Traded...
A2 - 2025-04-24T18:50:47Z - CERo Therapeutics Stock Spikes 42% On Clinical Trial Site Announcement For AML Treatment...
A3 - 2025-04-24T17:42:56Z - Wall Street-Heavily Traded...
A4 - 2025-04-24T17:05:54Z - 12 Health Care Stocks Moving In Thursday's Intraday Session - CERo Therapeutics Hldgs (NASDAQ:CERO),...
A5 - 2025-04-24T17:20:57Z - Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results - ASGN (NYSE:ASGN), Bristol-Myers Squibb (N...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CERO_OUT_7 [2025-04-24 15:45:02 -0400] 1181 Bytes | 328 tokens | Cum: 2551 tkns (31.89% of 8k)
==========================================================================

Showing A2 (chunk 1 of 2): A2:
**CERo Therapeutics Stock Spikes 42% On Clinical Trial Site Announcement For AML Treatment**Date: 2025-04-24Source: {'uri': 'rttnews.com', 'dataType': 'news', 'title': 'RTTNews'}URL: https://www.rttnews.com/3531529/cero-therapeutics-stock-spikes-42-on-clinical-trial-site-announcement-for-aml-treatment.aspxCERo Therapeutics Holdings, Inc. (CERO) soared 41.97 percent to $1.12, gaining $0.33 during Thursday's trading, after announcing that the Sarah Cannon Research Institute at Colorado Blood Cancer Institute will serve as a key clinical trial site for its Phase 1 study of CER-1236, a next-generation T cell therapy targeting acute myeloid leukemia.

The stock opened at $0.88 and has traded between $0.88 and $1.42 today, surging from the previous close of $0.80. Volume exploded to over 66 million shares, vastly exceeding the average volume of 686,000.

CERO is trading well above its 52-w

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CERO_OUT_9 [2025-04-24 15:45:03 -0400] 471 Bytes | 130 tokens | Cum: 2683 tkns (33.54% of 8k)
==========================================================================

Showing A2 (chunk 2 of 2): eek low of $0.5340 but remains far below its high of $171.00.

Patient enrollment is underway, with first dosing expected by June.

For comments and feedback contact: [email protected]

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CERO_OUT_11 [2025-04-24 15:45:03 -0400] 798 Bytes | 200 tokens | Cum: 2885 tkns (36.06% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-22 8-K Item 1.01 Entry into a Material Definitive Agrmt.

Private Placement

Securities Purchase Agrmt

On April 21, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the Company ), entered into a Securities Purchase Agrmt (the Securities Purchase Agrmt ...

S2 - 2025-04-15 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper of CERo.

The following discussion and analysis of CERos financial condition and results of operations should be read in conjunction with our audited CONS financial statements a...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CERO_OUT_13 [2025-04-24 15:45:04 -0400] 1181 Bytes | 277 tokens | Cum: 3164 tkns (39.55% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 1.01 Entry into a Material Definitive Agreement.

Private Placement

Securities Purchase Agreement

On April 21, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the Company ), entered into a Securities Purchase Agreement (the Securities Purchase Agreement ) with certain accredited investors named therein (the PIPE Investors ). Pursuant to the Securities Purchase Agreement, up to 10,000 shares of the Companys Series D convertible preferred stock, par value $0.0001 per share (the Series D Preferred Stock ) shall be purchased for an aggregate purchase price of up to $8 million in one or more closings (each a Closing ). On April 22, 2025, pursuant to the Securities Purchase Agreement, the Company issued and sold, and the PIPE Investors purchased, in a private placement (the Private Placement ): 6,250 shares of the Series D Preferred Stock for aggregate proceeds of

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CERO_OUT_15 [2025-04-24 15:45:05 -0400] 1181 Bytes | 254 tokens | Cum: 3420 tkns (42.75% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): approximately $5 million, paid in cash or through the transfer of certain Transfer Shares (as defined in the Securities Purchase Agreement) in lieu of cash. The date of the first closing is referred to as the First Closing Date . Each additional closing of the Private Placement is at the option of the PIPE Investors upon notice to the Company and subject to satisfaction of customary closing conditions.

Series D Preferred Stock

On the First Closing Date, the Company will designate 12,500 shares of the Companys authorized and unissued preferred stock as Series D Preferred Stock (the Series D Shares ) and establish the rights, preferences and privileges of the Series D Preferred Stock pursuant to the Certificate of Designations of Rights and Preferences of the Series D Preferred Stock (the Certificate of Designations ), to be filed with the Secretary of State of the State of Delaware, a

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CERO_OUT_17 [2025-04-24 15:45:05 -0400] 1181 Bytes | 264 tokens | Cum: 3686 tkns (46.08% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): s summarized below:

General . Each share of Series D Preferred Stock has a stated value of $1,000 per share and, when issued, the Series D Preferred Stock will be fully paid and non-assessable.

Ranking . The Series D Preferred Stock, with respect to the payment of dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company, ranks senior to all capital stock of the Company (including the Series A convertible preferred stock and the Series B convertible preferred stock, except for the Series C convertible preferred stock, which will rank pari passu ) unless the Required Holders (as defined in the Certificate of Designations) consent to the creation of other capital stock of the Company that is senior or equal in rank to the Series D Preferred Stock.

Dividends . The holders of Series D Preferred Stock will be entitled to dividends, on an as-if co

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CERO_OUT_19 [2025-04-24 15:45:06 -0400] 1181 Bytes | 262 tokens | Cum: 3950 tkns (49.38% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): nverted basis, equal to and in the same form as dividends actually paid on shares of the Companys common stock, par value $0.0001 per share (the Common Stock ), when and if actually paid.

Purchase Rights . If at any time the Company grants, issues or sells any options, convertible securities, or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the Purchase Rights ), then each holder of Series D Preferred Stock will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which such holder could have acquired if such holder had held the number of shares of Common Stock acquirable upon complete conversion of all the Series D Preferred Stock held by such holder immediately prior to the date as of which the record holders of shares of Commo

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CERO_OUT_21 [2025-04-24 15:45:07 -0400] 1181 Bytes | 255 tokens | Cum: 4207 tkns (52.59% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): n Stock are to be determined for the grant, issue or sale of such Purchase Rights at the Alternate Conversion Price (as defined below); subject to certain limitations on beneficial ownership.

Conversion Rights

Conversion at Option of Holder . Each holder of Series D Preferred Stock may convert all, or any part, of the outstanding Series D Preferred Stock, at any time at such holders option, into shares of the Common Stock (which converted shares of Common Stock are referred to as Conversion Shares herein) at the fixed Conversion Price of $0.78, which is subject to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions.

Voluntary Adjustment Right . Subject to the rules and regulations of the Nasdaq, the Company has the right, at any time after the Stockholder Approval Date (as defined below), with the written conse

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CERO_OUT_23 [2025-04-24 15:45:07 -0400] 790 Bytes | 178 tokens | Cum: 4387 tkns (54.84% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): nt of the Required Holders, to lower the fixed conversion price to any amount and for any period of time deemed appropriate by the board of directors of the Company (the Board ).

Alternate Conversion Upon a Triggering Event . Following the occurrence and during the continuance of a Triggering Event (as defined below), each holder may alternatively elect to convert the Series D Preferred Stock at the Alternate Conversion Price equal to the lesser of:

The applicable Conversion Price, and

the gre...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CERO_OUT_25 [2025-04-24 15:45:18 -0400] 7071 Bytes | 2008 tokens | Cum: 6397 tkns (79.96% of 8k)
==========================================================================

This is our set of metrics for CERo Therapeutics.
Please analyze the numbers.

+---------------------+------------------------+-----------------------+-------------------+
| Volume: 69,303,914 | Perf Month: 26.92% | Option/Short: No / No | Sales Y/Y TTM: - |
+---------------------+------------------------+-----------------------+-------------------+
| Avg Volume: 721.30K | Perf Quarter: -52.15% | Short Float: 9.35% | ROE: -4090.08% |
+---------------------+------------------------+-----------------------+-------------------+
| Rel Volume: 103.93 | Index: - | Short Ratio: 0.47 | ROI: -11090.59% |
+---------------------+------------------------+-----------------------+-------------------+
| RSI (14): 61.43 | Market Cap: 6.05M | Short Interest: 0.34M | Sales Surprise: - |
+---------------------+------------------------+-----------------------+-------------------+
| ATR (14): 0.16 | Shs Outstand: - | Beta: 0.62 | EPS Surprise: - |
+---------------------+------------------------+-----------------------+-------------------+
| SMA20: 53.83% | Shs Float: 3.66M | Sales Q/Q: - | P/E: - |
+---------------------+------------------------+-----------------------+-------------------+
| SMA50: -0.58% | Inst Own: 4.81% | Sales past 5Y: 0.00% | Earnings: - |
+---------------------+------------------------+-----------------------+-------------------+
| SMA200: -86.97% | Insider Own: 31.95% | Employees: 8 | |
+---------------------+------------------------+-----------------------+-------------------+
| Perf Week: 88.36% | Insider Trans: -88.62% | Debt/Eq: - | |
+---------------------+------------------------+-----------------------+-------------------+

The next section covers any insider trading by CERo Therapeutics officers or majority shareholders (if available).

Inside Trans: CERO THERAPEUTICS HOLDINGS, INC. (CERO) by ATWOOD BRIAN G (Unknown Title) on 2025-03-31
- Common Stock: 294460 shares at $0.0001 (I)
- Pre-Funded Warrant: 294460 shares at $0.0001 (D)

Inside Trans: CERO THERAPEUTICS HOLDINGS, INC. (CERO) by Ehrlich Christopher B (Chairman and CEO) on 2025-03-04
- Stock Option (Right to Buy): 119486 shares at $0 (D)

Inside Trans: CERO THERAPEUTICS HOLDINGS, INC. (CERO) by ATWOOD BRIAN G (Unknown Title) on 2025-03-04
- Stock Option (Right to Buy): 14936 shares at $0 (D)

Inside Trans: CERO THERAPEUTICS HOLDINGS, INC. (CERO) by Patel Shami (Unknown Title) on 2025-03-04
- Stock Option (Right to Buy): 14936 shares at $0 (D)

Inside Trans: CERO THERAPEUTICS HOLDINGS, INC. (CERO) by Byrnes Michael (Unknown Title) on 2025-03-04
- Stock Option (Right to Buy): 17923 shares at $0 (D)

Inside Trans: CERO THERAPEUTICS HOLDINGS, INC. (CERO) by Rolfe Lindsey (Unknown Title) on 2025-03-04
- Stock Option (Right to Buy): 17923 shares at $0 (D)

Inside Trans: CERO THERAPEUTICS HOLDINGS, INC. (CERO) by LAPORTE KATHLEEN (Unknown Title) on 2025-03-04
- Stock Option (Right to Buy): 17923 shares at $0 (D)

Inside Trans: CERO THERAPEUTICS HOLDINGS, INC. (CERO) by LAPORTE KATHLEEN (Unknown Title) on 2025-02-24
- Stock Option (Right to Buy): 127500 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -5365136.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.15
Average Volume: 4108937.95
30-Day High: 1.15
30-Day Low: 0.585

[Detailed Financials: Q2 2024]
- Total Assets: $7,370,765.00
- Total Liabilities: $9,852,633.00
- Total Equity: $-2,481,868.00
- Current Assets: $4,245,911.00
- Current Liabilities: $8,779,323.00

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: $-2,448,654.00
- Gross Profit: N/A
- Operating Income: $-5,148,237.00
- Earnings Per Share (EPS): -0.15

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: N/A

[Detailed Financials: Q1 2024]
- Total Assets: $9,052,656.00
- Total Liabilities: $13,031,753.00
- Total Equity: $-3,979,097.00
- Current Assets: $5,501,205.00
- Current Liabilities: $11,651,445.00

[Income Statement: Q1 2024]
- Revenue: $0.00
- Net Income: $-1,727,483.00
- Gross Profit: N/A
- Operating Income: $-3,654,937.00
- Earnings Per Share (EPS): -0.12

[Cash Flow Statement: Q1 2024]
- Net Cash Flow: N/A
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of CERo Therapeutics (CERO).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about CERo Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because CERO is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for CERO.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, CERO could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect CERO to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of CERo Therapeutics.

11) ETHICAL_RATING[]
Rate CERo Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of CERo Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

CERO_IN_27 [2025-04-24 15:45:19 -0400] 126 Bytes | 29 tokens | Cum: 6624 tkns (82.80% of 8k)
==========================================================================

====================================
[2025-04-24 15:45:19] # Analysis Completed
Elapsed Time: 19.84 seconds